News
04 Aug 2017
International Company Crystal Pharmatech Finds CCIT An Optimal Spot for First US Location
04 Aug 2017
en
This milestone further demonstrates Candoo's expertise in formulation and biopharmaceutics to achieve bioequivalence among different polymorphs and/or salts. For new chemical entities (NCE), it is useful to conduct bridging studies in late clinical stage where a more stable or favorable polymorph or salt is identified, or to show BE between clinical and commercial formulations as per regulatory requirements. For generics, this technique will help clients to speed up the development of first-to-file (Paragraph IV) products and get products launched sooner.
